Cryolife, Inc. 10-Q Summary: Quarter Ended March 31, 1999
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Cryolife, Inc., covering the three months ended March 31, 1999. The company specializes in cryopreservation services for human tissues (heart valves, vascular, and connective tissues) and the commercialization of surgical products such as BioGlue surgical adhesive. The filing notes that operating results for the quarter are not necessarily indicative of full-year expectations.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $16.3 million | $14.6 million |
| Net Income | $1.38 million | $1.17 million |
| Earnings Per Share (Diluted) | $0.11 | $0.12 |
| Operating Cash Flow | ($2.24 million) used | $0.70 million provided |
| Cash and Equivalents | $8.1 million | $0.1 million |
| Working Capital | $61.7 million | N/A |
| Current Ratio | 8.0 to 1 | N/A |
| Total Debt (Long-term + Current) | $6.0 million | N/A |
Note: Debt figures derived from balance sheet line items including convertible debentures, capital leases, and long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 12% year-over-year. Preservation services and products rose 11% to $16.1 million, driven by increased demand for vascular and connective tissues and international sales of BioGlue.
- Product Mix Shift: Heart valve revenues decreased 8% due to fewer Ross procedures, while vascular tissue revenues surged 39% and connective tissue revenues rose 33%.
- Margin Compression: Gross margins on preservation services declined as the mix shifted toward lower-margin vascular/connective tissues and OEM manufacturing, with cost of goods sold rising to 46% of revenue from 38%.
- Interest Income: The company swung from a net interest expense of $430,000 in 1998 to net interest income of $306,000 in 1999, largely due to invested proceeds from a 1998 equity offering and debt repayment.
- Cash Flow Reversal: Operating cash flow turned negative ($2.24 million used) compared to positive in 1998, primarily due to a $2.0 million increase in accounts receivable and payments for BioGlue lab expansion.
Outlook, Risks, and Management Commentary
- Liquidity: Management anticipates that remaining proceeds from the 1998 offering and cash from operations will meet needs for the next 12 months. However, future funding may be required for FDA approvals, marketing expansion, and manufacturing capacity.
- Seasonality: Heart valve demand is seasonal, peaking in Q2 and Q3. Connective tissue demand may also be seasonal due to elective procedures. Vascular and BioGlue sales are not considered seasonal.
- Year 2000 Compliance: The company estimates compliance costs under $50,000. A delay in the clinical tracking database implementation is the principal risk, though management does not expect a material adverse effect.
- Strategic Initiatives: The company is seeking an equity investor for its FibRx technology to fund commercial development separately. It is also commercializing BioGlue in European and other overseas markets.
- Risks: Key risks include the timing of FDA approvals, market acceptance of new products, and the availability of additional financing on acceptable terms.
Investor Verification Checklist
- Verify the sustainability of the 39% growth in vascular tissue shipments and the 33% growth in connective tissue shipments.
- Confirm the timeline and regulatory status of the BioGlue surgical adhesive in international markets.
- Assess the impact of the shift in product mix on long-term gross margin stability.
- Monitor the status of the FibRx technology spin-off or equity placement strategy.
- Review the progress of the clinical tracking database upgrade to ensure Year 2000 compliance and FDA adherence.